SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: arnie h who wrote (934)10/25/1999 11:04:00 PM
From: Cacaito   of 1386
 
Check the following link, is about BLA, but probably very similar to NDA (dexanabinol will be an NDA), pay special attention to the "surrogate" points:

www3.techstocks.com,

full document should be somewhere in FDA manuals.

Decreasing intracranial pressure with sustained systemic
pressure is a significant surrogate point, on top of that improvement in long term dissabilities will give dexanabinol
good chances for approval.

Decrease mortality will be a sure thing, but there are good chances even if just a trend is suggested plus above will give dexanabinol very good chances.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News